The further reduction in adenoma number with the sulindac+PP combination compared with sulindac alone suggests an increased sensitivity of the Dclk1+ cell–induced Apc-mutant adenoma cells compared with the adenoma cells in the constitutive Apcmin/+ model. Here, DCLK1 is linked to adenoma.